Minimal Residual Disease (MRD) Negativity and Lenalidomide Maintainence Therapy are Associated with Superior Survival Outcomes in Multiple Myeloma

被引：0

作者：

Gopalakrishnan, Ragisha ^{[1
]}

Engelhardt, Brian G. ^{[1
]}

Sengsayedeth, Salyka ^{[1
]}

Culos, Kathryn A. ^{[2
]}

Byrne, Michael T. ^{[3
]}

Goodman, Stacey ^{[1
]}

Savani, Bipin N. ^{[3
]}

Chinratanalab, Wichai ^{[1
]}

Jagasia, Madan ^{[4
]}

Cornell, Robert Frank ^{[1
]}

Kassim, Adetola A. ^{[3
]}

机构：

[1] Vanderbilt Univ, Med Ctr, Nashville, TN USA

[2] Vanderbilt Univ, Med Ctr, Pharm, Nashville, TN USA

[3] Vanderbilt Univ, Med Ctr, Hematol Oncol, Nashville, TN USA

[4] Vanderbilt Univ, Med Ctr, Vanderbilt Ingram Canc Ctr, Nashville, TN USA

来源：

BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION | 2018年 / 24卷 / 03期

关键词：

D O I：

10.1016/j.bbmt.2017.12.660

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：S76 / S77

页数：2

共 50 条

[41] Predictors of unsustained measurable residual disease (MRD) negativity in transplant-eligible multiple myeloma (MM) patients
Guerrero, Camila
Puig, Noemi
Cedena, Teresa
Calasanz, Maria-Jose
Gutierrez, Norma
Fernandez-Guijarro, Manuela
Oriol, Albert
Rios, Rafael
Hernandez Garcia, Miguel Teodoro
Martinez-Martinez, Rafael
Bargay, Joan
de Arriba de la Fuente, Felipe
Palomera, Luis
Pilar Gonzalez-Rodriguez, Ana
Gonzalez-Perez, Marta-Sonia
Orfao, Alberto
Mateos, Maria-Victoria
Martinez-Lopez, Joaquin
Rosinol, Laura
Blade, Joan
Lahuerta Palacios, Juan Jose
San-Miguel, Jesus
Paiva, Bruno
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S7 - S8
[42] Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone With Minimal Residual Disease Response-Adapted Therapy in Newly Diagnosed Multiple Myeloma
Costa, Luciano J.
Chhabra, Saurabh
Medvedova, Eva
Dholaria, Bhagirathbhai R.
Schmidt, Timothy M.
Godby, Kelly N.
Silbermann, Rebecca
Dhaka, Binod
Bal, Susan
Gid, Smith
D'Souza, Anita
Hall, Aric
Hardwick, Pamela
Omel, James
Cornell, Robert F.
Had, Parameswaran
Callander, Natalie S.
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (25) : 2901 - +
[43] Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma
Perrot, Aurore
Lauwers-Cances, Valerie
Corre, Jill
Robillard, Nelly
Hulin, Cyrille
Chretien, Marie-Lorraine
Dejoie, Thomas
Maheo, Sabrina
Stoppa, Anne-Marie
Pegourie, Brigitte
Karlin, Lionel
Garderet, Laurent
Arnulf, Bertrand
Doyen, Chantal
Meuleman, Nathalie
Royer, Bruno
Eveillard, Jean-Richard
Benboubker, Lotfi
Dib, Mamoun
Decaux, Olivier
Jaccard, Arnaud
Belhadj, Karim
Brechignac, Sabine
Kolb, Brigitte
Fohrer, Cecile
Mohty, Mohamad
Macro, Margaret
Richardson, Paul G.
Carlton, Victoria
Moorhead, Martin
Willis, Tom
Faham, Malek
Anderson, Kenneth C.
Harousseau, Jean-Luc
Leleu, Xavier
Facon, Thierry
Moreau, Philippe
Attal, Michel
Avet-Loiseau, Herve
Munshi, Nikhil
BLOOD, 2018, 132 (23) : 2456 - 2464
[44] A sensitive technique for detection of minimal residual disease (MRD) in myeloma patients
JeddiTehrani, M
Gigliotti, D
Osterborg, A
Fagerberg, J
Mellstedt, H
BRITISH JOURNAL OF HAEMATOLOGY, 1996, 93 : 488 - 488
[45] Prospective Trial Using Multimodal Measurable Residual Disease Negativity to Guide Discontinuation of Maintenance Therapy in Multiple Myeloma (MRD2STOP)
Derman, Ben A.
Major, Ajay
Major, Sarah
Wolfe, Brittany D.
Gorski, Martha
Cooperrider, Jennifer H.
Andreatos, Evangelia
Jiang, Ken
Buckley, Karson
McIver, Amanda
Stefka, Andrew
Jakubowiak, Andrzej
BLOOD, 2022, 140 : 2108 - 2109
[46] PROGNOSTIC VALUE OF DEEP SEQUENCING APPROACH FOR MINIMAL RESIDUAL DISEASE (MRD) DETECTION IN MULTIPLE MYELOMA PATIENTS
Martinez-Lopez, J.
Lahuerta, J. J.
Pepin, F.
Gonzalez, M.
Barrio, S.
Ayala, R.
Puig, N.
Montalban, M. A.
Paiva, B.
Weng, L.
Jimenez, C.
Sopena, M.
Cedena, T.
Rapado, I.
Mateo, M. V.
Rosinol, L.
Oriol, A.
Blanchard, M. J.
Martinez, R.
Blade, J.
San Miguel, J.
Faham, M.
Garcia-Sanz, R.
HAEMATOLOGICA, 2014, 99 : 494 - 494
[47] GROWING ACCEPTANCE OF MINIMAL RESIDUAL DISEASE (MRD) AS A PRIMARY ENDPOINT IN MULTIPLE MYELOMA (MM) CLINICAL TRIALS
Jones, C.
Watson, A. T.
Wolkensdorfer, Z.
VALUE IN HEALTH, 2024, 27 (06) : S34 - S35
[48] New Alternatives for the Evaluation of Minimal Residual Disease (MRD) Detection By Next Generation Sequencing in Multiple Myeloma
Medina, Alejandro
Jimenez, Cristina
Puig, Noemi
Sanchez-Vega, Beatriz
Flores-Montero, Juan
Gonzalez, Marcos
Calasanz, Maria Jose
Ayala, Rosa M.
Sarasquete, Maria E.
Paiva, Bruno
Cedena, Maria Teresa
Fernandez-Mercado, Marta
Rapado, Inmaculada
Rosinol, Laura
Ocio, Enrique M.
Oriol, Albert
Alcoceba, Miguel
Hernandez, Miguel T.
Martinez, Rafael Martinez
Mateos, Maria-Victoria
Lahuerta, Juan-Jose
Blade, Joan
Orfao, Alberto
San Miguel, Jesus F.
Martinez-Lopez, Joaquin
Garcia-Sanz, Ramon
BLOOD, 2017, 130
[49] THE ACCEPTANCE OF MINIMAL RESIDUAL DISEASE (MRD) AS A CLINICAL ENDPOINT IN MULTIPLE MYELOMA (MM): A TARGETED LITERATURE REVIEW
Grandy, W.
Kachouh, P.
Yang, B.
VALUE IN HEALTH, 2022, 25 (01) : S189 - S190
[50] Prognostic Value Of Deep Sequencing Approach For Minimal Residual Disease (MRD) Detection In Multiple Myeloma Patients
Martinez-Lopez, Joaquin
Laheurta, Juan Jose
Pepin, Francois
Gonzalez, Marcos
Barrio, Santiago
Ayala, Rosa M.
Puig, Noemi
Montalban, Maria Angeles
Paiva, Bruno
Weng, Li
Jimenez, Cristina
Sopena, Maria
Cedena, Teresa
Rapado, Inmaculada
Mateo, Maria Victoria
Rosinol, Laura
Oriol, Albert
Blanchard, Maria Jesus
Martinez, Rafael
Blade, Joan
San Miguel, Jesus F.
Faham, Malek
Garcia-Sanz, Ramon
BLOOD, 2013, 122 (21)

← 1 2 3 4 5 →